Filorexant

DB12158InvestigationalSmall molecule

Filorexant has been used in trials studying the prevention and treatment of Migraine, Headache, Polysomnography, Diabetic Neuropathy, Painful, and Major Depressive Disorder, Recurrent.

Mechanism: Pharmacologically active on Orexin/Hypocretin receptor type 1 and Orexin receptor type 2
Curator reviewed
Formula / weight: C₂₄H₂₅FN₄O₂ · 420.488 g/mol (avg)
Code names: MK-6096

Resolves to

Compound

UNIIE6BTT8VA5ZCAS1088991-73-4ChEMBLCHEMBL2107822PubChem25128145

Structure

InChIKeyNPFDWHQSDBWQLH-QZTJIDSGSA-NSMILESC[C@@H]1CC[C@@H](COC2=CC=C(F)C=N2)CN1C(=O)C1=CC(C)=CC=C1C1=NC=CC=N1

Targets

O43613HCRTR1O43614HCRTR2

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Filorexant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account